ALTITUDE-AD
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug (ACU193) in Participants With Early Alzheimer’s Disease.
The primary purpose of this study is to evaluate the efficacy of sabirnetug (ACU193) infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer’s disease.
For more information, visit www.clinicaltrials.gov, NCT identifier NCT06335173
